Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BHP Billiton Limited (BHP) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

BHP Billiton LimitedTrade
Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

BHP Billiton Limited vs Citius Pharmaceuticals Inc — how do they compare? BHP Billiton Limited trades at $90.9 (market cap $229.15B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: BHP Billiton Limited is far larger — about 11451.8× Citius Pharmaceuticals Inc's market cap, and BHP Billiton Limited pays a 2.95% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

BHPCTXR
Market Cap
$229.15B$20.01M
Sector
Basic MaterialsHealth
52-Week High
$93.15$1.82
52-Week Low
$52.14$0.48
Enterprise Value
$243.35B$16.23M
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BHP Billiton Limited

No Aura AI signal available yet.

Citius Pharmaceuticals Inc

CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.

The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.

Returns comparison

Trailing returns across standard periods

About BHP Billiton Limited

BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.

Read more on BHP

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR